| Literature DB >> 28322979 |
Mercedes Pérez-Hernández1, María Encarnación Fernández-Valle2, Ana Rubio-Araiz1, Rebeca Vidal1, María Dolores Gutiérrez-López1, Esther O'Shea3, María Isabel Colado4.
Abstract
The recreational drug of abuse, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier (BBB) integrity in rats through an early P2X7 receptor-mediated event which induces MMP-9 activity. Increased BBB permeability often causes plasma proteins and water to access cerebral tissue leading to vasogenic edema formation. The current study was performed to examine the effect of a single neurotoxic dose of MDMA (12.5 mg/kg, i.p.) on in vivo edema development associated with changes in the expression of the perivascular astrocytic water channel, AQP4, as well as in the expression of the tight-junction (TJ) protein, claudin-5 and Evans Blue dye extravasation in the hippocampus of adult male Dark Agouti rats. We also evaluated the ability of the MMP-9 inhibitor, SB-3CT (25 mg/kg, i.p.), to prevent these changes in order to validate the involvement of MMP-9 activation in MDMA-induced BBB disruption. The results show that MDMA produces edema of short duration temporally associated with changes in AQP4 expression and a reduction in claudin-5 expression, changes which are prevented by SB-3CT. In addition, MDMA induces a short-term increase in both tPA activity and expression, a serine-protease which is involved in BBB disruption and upregulation of MMP-9 expression. In conclusion, this study provides evidence enough to conclude that MDMA induces edema of short duration due to BBB disruption mediated by MMP-9 activation.Entities:
Keywords: AQP4; Blood-brain barrier; Edema; Evans Blue dye (PubChem CID: 24832074); MDMA; MDMA hydrochloride (PubChem CID: 71285); MMP-9; SB-3CT; SB-3CT (PubChem CID: 9883002)
Mesh:
Substances:
Year: 2017 PMID: 28322979 DOI: 10.1016/j.neuropharm.2017.03.019
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250